Greenland Mines Ltd 10-Q

Item 5. Other Information During the three months ended September 30, 2024, the Company’s Board of Directors adopted an Insider Trading Policy which applies to the Company’s officers, directors, employees and consultants, a copy of which is attached hereto as Exhibit 19.1, to this Quarterly Report on Form 10-Q and incorporated herein by reference. Item 6. Exhibits The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report. Exhibit No. Description 19.1* Klotho Neurosciences, Inc. Insider Trading Policy 31.1* Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2* Certification of Principal Accounting and Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1** Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.2** Certification of Principal Accounting and Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS* Inline XBRL Instance Document 101.SCH* Inline XBRL Taxonomy Extension Schema Document 101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB* Inline XBRL Taxonomy Extension Labels Linkbase Document 101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document 104* Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit) * Filed herewith. ** Furnished herewith. This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filings of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. 21 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KLOTHO NEUROSCIENCES, INC. Date: November 19, 2024 By: /s/ Joseph A. Sinkule Name: Joseph A. Sinkule Title: Chief Executive Officer (Principal Executive Officer) Date: November 19, 2024 By: /s/ Jeffrey LeBlanc Name: Jeffrey LeBlanc Title: Chief Financial Officer (Principal Accounting Officer) 22